GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (NYSE:IQV) » Definitions » 14-Day RSI

IQVIA Holdings (IQVIA Holdings) 14-Day RSI

: 29.75 (As of Today)
View and export this data going back to 2013. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-19), IQVIA Holdings's 14-Day RSI is 29.75.

The industry rank for IQVIA Holdings's 14-Day RSI or its related term are showing as below:

IQV's 14-Day RSI is ranked better than
86.18% of 246 companies
in the Medical Diagnostics & Research industry
Industry Median: 41.88 vs IQV: 29.75

Competitive Comparison

For the Diagnostics & Research subindustry, IQVIA Holdings's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IQVIA Holdings 14-Day RSI Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's 14-Day RSI falls into.



IQVIA Holdings  (NYSE:IQV) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IQVIA Holdings  (NYSE:IQV) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


IQVIA Holdings 14-Day RSI Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


IQVIA Holdings (IQVIA Holdings) Business Description

Traded in Other Exchanges
Address
2400 Ellis Road, Durham, NC, USA, 27703
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Executives
Kevin C Knightly officer: Pres Info & Tech Solutions 1499 POST ROAD, FAIRFIELD CT 06824
Panagos Constantinos officer: See Remarks 4280 EMPEROR BLVD, DURHAM NC 27703
Eric Sherbet officer: See Remarks 100 IMS DRIVE, PARSIPPANY NJ 07054-4235
Keriann Cherofsky officer: See Remarks 4280 EMPEROR BLVD, DURHAM NC 27703
Sheila A Stamps director C/O CIT GROUP, 1 CIT DRIVE, ATTN: GENERAL COUNSEL, LIVINGSTON NJ 07039
Morris Leslie Wims director 4280 EMPEROR BLVD, DURHAM NC 27703
John Connaughton director, 10 percent owner BAIN CAPITAL PARTNERS LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Ronald E Bruehlman officer: See Remarks C/O IQVIA HOLDINGS, INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
Ronald A Rittenmeyer director 5400 LEGACY DRIVE, PLANO TX 75024
Ari Bousbib director, officer: Chairman, CEO & Pres UNITED TECHNOLOGIES CORP, ONE FINANCIAL PLAZA, HARTFORD CT 06101
W Richard Staub officer: See Remarks
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Michael J Evanisko director BRAUN CONSULTING, 20 W KINZIE STREET SUITE 1600, CHICAGO IL 60610
Michael R Mcdonnell officer: Chief Financial Officer C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
John M. Leonard director C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139

IQVIA Holdings (IQVIA Holdings) Headlines